Cadonilimab  (Synonyms: 卡度尼利单抗; AK104)

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC)^[1][2][3][4].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Chimeric; Humanized

PD1^[1]

Cadonilimab (0-100 nM, 10-120 分钟) 经碘修饰后对 Jurkat-CTLA4 和 Jurkat-PD1 细胞保持高亲和力^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

¹²⁴I 修饰的 Cadonilimab (3.7 MBq，尾静脉注射，单剂量) 在 MC38-hPD-L1 细胞异种移植人源化小鼠的脾脏和肿瘤部位大量富集，并导致肿瘤部位 PD1/CTLA4 阳性免疫细胞的富集^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2394841-59-7

液体

Colorless to light yellow

卡度尼利单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa-[scFv-heavy-lambda]2

• 
  Immobilized Cadonilimab can bind Human PD-1 Protein (ECD, His Tag). The EC₅₀ for this effect is 0.197 ng/mL.
• 
  Immobilized Cadonilimab can bind Human CTLA-4 Protein (His Tag). The EC₅₀ for this effect is 3.07 ng/mL.

• [1]. Antonarelli G, et al. Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals (Basel). 2021 Aug 31;14(9):884.  [Content Brief]

  [2]. Kaplon H, et al. Antibodies to watch in 2022. MAbs. 2022 Jan-Dec;14(1):2014296.  [Content Brief]

  [3]. Chen PY, et al. Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab. Front Immunol. 2023 Aug 3;14:1188523.  [Content Brief]

  [4]. Hou X, et al. Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice. Biomed Pharmacother. 2024 Jun;175:116669.  [Content Brief]